Obesity Medicine

Latest News

Mifepristone Reduced HbA1c, Body Weight in Adults with Hypercortisolism and Inadequately Controlled T2D: CATALYST Trial Treatment Phase
Mifepristone Reduced HbA1c, Body Weight in Adults with Hypercortisolism and Inadequately Controlled T2D: CATALYST Trial Treatment Phase

June 24th 2025

ADA 2025: Mifepristone lowered HbA1c levels by about 1.5% over 24 weeks vs placebo among participants with hypercortisolism and inadequately controlled T2D.

 Bimagrumab + Semaglutide Highly Effective for Loss of Fat, Preservation of Muscle in Phase 2b BELIEVE Trial / image credit American Diabetes Association
Bimagrumab + Semaglutide Highly Effective for Loss of Fat, Preservation of Muscle in Phase 2b BELIEVE Trial

June 24th 2025

Orforglipron, Investigational Oral GLP-1, Cut HbA1c and Body Weight in People with T2D
Orforglipron, Investigational Oral GLP-1, Cut HbA1c and Body Weight in People with T2D

June 23rd 2025

Primary Care-Led Weight Management Intervention Prevents Weight Gain and Enhances Revenue: New Research
Primary Care-Led Weight Management Intervention Prevents Weight Gain and Enhances Revenue: New Research

June 23rd 2025

Weight Cycling Ups Risk for Heart Failure by 50%, Other Metabolic Diseases by Up to 30%: New Data
Weight Cycling Ups Risk for Heart Failure by 50%, Other Metabolic Diseases by Up to 30%: New Data

June 23rd 2025

More News

© 2025 MJH Life Sciences

All rights reserved.